You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.
Access MyCepheid
Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focus on cancers of the breast, bladder, and blood. Harnessing the power of quantitative PCR technology and the world’s most popular molecular diagnostics platform1, Cepheid oncology products provide on-site, on-demand, standardized, and reliable results.
Cepheid expanded its breast cancer diagnostics capabilities with the acquisition of OncoMark, a company that developed technology to estimate the likelihood of early-stage breast cancer recurrence after treatment. Optimized to run on the Cepheid GeneXpert® systems, the technology uses a proprietary algorithm to produce a binary risk score (high risk vs low risk) to predict the likelihood of disease recurrence in the next 10 years.
Cepheid also continues to offer the Xpert® Breast Cancer STRAT4 biomarker test in countries accepting the CE-IVD mark.
To learn more, contact the Cepheid Medical and Scientific Affairs and Strategy team for Oncology at: MedSci.Oncology@Cepheid.com.
Xpert Breast Cancer STRAT-4 is not available in the US.
In this video, we see Dr. Craft consulting with Dr. Tanner, the on-site Pathologist, representing two of the members of the local cross-functional oncology team most familiar with the patient, Elizabeth.
The high sensitivity of the Cepheid BCR-ABL test, Xpert BCR-ABL Ultra*, allows for monitoring of disease even at low levels, thereby providing an essential aid for clinicians to manage their patients with CML, using IS-standardized molecular testing.
Xpert Bladder Cancer Detection and Xpert Bladder Cancer Monitor* are two easy to use, non-invasive bladder cancer tests. Xpert Bladder Cancer Detection* is intended to detect the presence of bladder cancer in patients with hematuria. Xpert Bladder Cancer Monitor* is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer. Both tests measure five bladder cancer-specific biomarkers and require only a urine sample from
the patient.
Visit the Xpert Bladder Cancer Detection Product Page
Xpert Breast Cancer STRAT4* is an mRNA-based test that standardizes and simplifies the assessment of ESR1, PGR, ERBB2, and MKi-67 breast cancer biomarkers. In less than 2 hours, the test provides objective and reproducible results that are well-correlated with central lab IHC/ISH methods. Clear and accurate results empower pathologists and oncologists.
Our BCR-ABL test is playing a pivotal role in Cepheid’s vision of making molecular testing accessible to patients everywhere. In 2012, Cepheid partnered with The Max Foundation, an organization that channels humanitarian donations of life-saving oncology products to underserved populations in countries where those products are not locally available.
Through this collaboration of shared values, Cepheid offers compassion pricing of its GeneXpert IV instruments and Xpert BCR-ABL test for CML patients in specified low- and middle-income countries. Cepheid is also a proud sponsor of the Max Foundation initiative, My PCR, a patient driven program with the mission of educating all CML patients about the importance of monitoring their treatment with PCR testing.
More than a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with the GeneXpert® System. The complicated process of nucleic acid extraction, amplification and detection is all carried out within each single use cartridge. By making complex technology easy to use, our GeneXpert® cartridge has become the symbol of the Molecular Revolution. Using advanced microfluidics, all aspects of the testing process are handled within the cartridge chambers, minimizing the risk of cross contamination. Each cartridge is standardized and comes with internal controls, making running extra standard curves obsolete.
Our oncology tests quickly and accurately characterize multiple cancer markers using the same game changing system.
1. Based on July 2019 market research conducted by Kalorama Information with sample respondents in select countries.
2. CE IVD and US-IVD. In Vitro Diagnostic Medical Device. Not available in all countries.
3. CE IVD. In Vitro Diagnostic Medical Device. Not available in all counties. Not available in the United States.
